Trials — ASCO 2026
The primary artifact of this vault: one Markdown file per trial / readout. ASCO 2026 is a clinical-readout meeting, so the unit of analysis is the trial — not the speaker, not the tool, not the company.
Status: Built post-meeting. 46 trial pages with verified results, reconciled against ASCO press releases, company releases, simultaneous journal publications, and trade-press recaps as embargoes lifted (May 29 – Jun 2, 2026). For the cross-cutting synthesis see themes.md; for the chronological narrative see the day digests (Day 1 … Day 5).
Plenary (Sun May 31, LBA1–5)
| # |
Trial |
Sponsor |
Indication |
Headline result |
Practice-changing? |
| LBA1 |
PROTEUS |
J&J / Janssen |
Perioperative high-risk localized prostate |
pCR/MRD 8.9% vs 1.0%; MFS HR 0.80 (BICR); subsequent therapy delayed 33 mo (N=2,109); NEJM |
Yes |
| LBA2 |
SARC041 |
Lilly (IIT) |
Advanced dedifferentiated liposarcoma |
mPFS 9.7 vs 1.5 mo (HR ≈0.38, ~62% reduction); first positive Ph3 in DDLPS |
Yes |
| LBA3 |
LIBRETTO-432 |
Lilly (Loxo) |
Adjuvant RET-fusion+ NSCLC |
83% reduction in recurrence/death (EFS); first adjuvant RET TKI |
Yes |
| LBA4 |
HARMONi-6 |
Akeso / Summit |
1L squamous NSCLC |
mOS 27.89 vs 23.69 mo vs tislelizumab+chemo; first OS win for PD-1×VEGF |
Pending |
| LBA5 |
RASolute 302 |
Revolution Medicines |
2L metastatic PDAC (RAS) |
mOS 13.2 vs 6.7 mo (HR 0.40, P<.0001); first pan-RAS Ph3 win in PDAC; NEJM |
Yes |
Lung
| Trial |
Day |
Result |
PC? |
| WU-KONG28 |
Fri |
1L sunvozertinib vs chemo, EGFR exon20ins NSCLC: mPFS 10.3 vs 7.5 mo (HR 0.65); NEJM |
Yes |
| CROWN (7-yr) |
Fri |
Lorlatinib vs crizotinib ALK+ NSCLC: mPFS NR vs 9.1 mo (HR 0.19); 55% vs 3% PF at 7 yr |
No (confirm.) |
| OptiTROP-Lung05 |
Fri |
Sac-TMT + pembro vs pembro, 1L PD-L1+ NSCLC: mPFS NR vs 5.7 mo (HR 0.35) |
Pending |
| ANVIL / ALCHEMIST EA5142 |
— |
Adjuvant nivolumab, EGFR/ALK-WT NSCLC: no DFS benefit (HR 0.97) — negative |
No |
| TRIPLEX |
— |
Thoracic RT + chemo-IO, ES-SCLC: terminated early for excess toxicity |
No |
| CHRYSALIS-2 (Cohort C) |
— |
1L ami + lazertinib, atypical EGFR NSCLC: mOS 41.0 mo, ORR 57% |
Pending |
| IMforte (subtype) |
Sun |
Lurbinectedin + atezo 1L SCLC maintenance — transcriptomic subtype subanalysis |
Pending |
GI
| Trial |
Day |
Result |
PC? |
| BREAKWATER (Cohort 3) |
Sun |
1L EC + FOLFIRI, BRAF V600E mCRC: mPFS 15.2 vs 8.3 mo (HR 0.44); OS NR vs 20.3 mo |
Yes |
| HERIZON-GEA-01 |
Mon |
Zanidatamab + chemo ± tisle, 1L HER2+ GEA: mOS 26.4 vs 19.2 mo (HR 0.72) |
Pending |
| HORIZON-CRC01 |
— |
Trastuzumab rezetecan, HER2+ chemo-refractory mCRC: mPFS 5.5 vs 2.8 mo (HR 0.33) |
Pending |
| EMERALD-3 |
— |
STRIDE + lenvatinib + TACE, HCC: mPFS 13.0 vs 9.8 mo (HR 0.70) |
Pending |
| OrigAMI-1 |
— |
Amivantamab biomarker analysis, RAS/BRAF-WT mCRC (AREG-high PFS 9.1 vs 4.5 mo) |
Pending |
| Alpha DaRT PDAC |
— |
EUS-guided intratumoral alpha-emitter, advanced PDAC: mOS ~11–17 mo (pooled Ph1/2) |
Pending |
| CT041 satri-cel (Cohort 3) |
Sat |
Claudin18.2 CAR-T sequential after 1L gastric: ORR 100% (4/4), mPFS-from-1L 20.9 mo |
No (n=5) |
| EPISODE-III |
— |
Adjuvant aspirin, stage III CRC: missed DFS (HR 0.84, P=.099) |
No |
GU
| Trial |
Day |
Result |
PC? |
| TALAPRO-3 |
— |
Tala + enza, HRR-altered mCSPC: rPFS HR 0.481 (BRCA HR 0.368); NEJM |
Pending |
| A-DREAM |
Sat |
ADT+ARPI interruption in exceptional mHSPC responders: 57.7% treatment-free at 18 mo |
Pending |
| ARACOG |
— |
Darolutamide vs enzalutamide cognition: −15.8% vs −36.1% MCCD (P=.009) |
Pending |
| NEXUS-01 |
Mon |
Nectin-4 ADC LY4052031, post-EV urothelial: ORR 33%, DOR 7.4 mo |
Pending |
| EV-302 / KEYNOTE-A39 (3.5-yr) |
— |
EV + pembro urothelial: mOS 33.6 vs 15.9 mo (HR 0.53) — mature update |
No (confirm.) |
| RAMPART |
— |
Adjuvant durva ± treme, resected RCC: durva mono missed DFS (HR 0.74) |
No |
| TiNivo-2 (final) |
— |
Tivo + nivo vs tivo, post-ICI mRCC: no benefit (mPFS 5.7 vs 7.4 mo) |
No |
Breast
| Trial |
Day |
Result |
PC? |
| ASCENT-04 / KEYNOTE-D19 |
Sun/Tue |
SG + pembro, 1L PD-L1+ mTNBC: mPFS 11.2 vs 7.8 mo (HR 0.65); subgroup-consistent |
Yes |
| SERENA-6 |
Tue |
ctDNA-guided switch to camizestrant, ESR1m HR+ MBC: PFS 16.0 vs 9.2 mo (HR 0.44) |
Pending |
| lidERA |
Sat |
Adjuvant giredestrant: iDFS HR 0.70 (30% reduction); N=4,170 |
Pending |
| evERA |
— |
Giredestrant + everolimus post-CDK4/6i: PFS 8.77 vs 5.49 mo (HR 0.56) |
Pending |
| persevERA |
Tue |
Giredestrant + palbociclib 1L: missed primary PFS (numerical, NS); N=992 |
No |
| NATALEE (gene expr.) |
Sat |
Adjuvant ribociclib iDFS consistent across PAM50 subtypes (HR 0.42–0.77) |
Pending |
| KN026-004 (Neo-Healer) |
Sat |
Neoadjuvant anbenitamab + chemo vs THP, HER2+: tpCR 62.4% vs 51.2% (P=.0099) |
Pending |
| DESTINY-Breast09 (durability) |
— |
T-DXd + pertuzumab 1L HER2+ mBC: durable responses (DOR 39.2 vs 26.4 mo) |
Pending |
| JSKN016 |
Mon |
First-in-class TROP2/HER3 bispecific ADC, late-line HER2− BC (early data) |
Pending |
| BWEL |
— |
Telephone weight-loss intervention: ~5.7% loss, improved physical function |
Pending |
Heme
| Trial |
Day |
Result |
PC? |
| MajesTEC-9 |
Fri |
Teclistamab vs PVd/Kd, RRMM: mPFS NR vs 8.2 mo (HR 0.29); NEJM |
Yes |
| SUCCESSOR-2 |
Fri |
MeziKd vs Kd, RRMM: mPFS 18.0 vs 8.3 mo (HR 0.48) |
Pending |
| frontMIND |
Sat |
Tafa + len + R-CHOP, 1L high-risk DLBCL/HGBL: PFS HR 0.75 (P=.019) |
Pending |
| EPCORE DLBCL-1 |
— |
Epcoritamab mono vs chemo, R/R DLBCL: PFS HR 0.74; first CD3×CD20 Ph3 mono |
Pending |
| PRIMAVERA |
Sat |
AZD3470 (PRMT5i) mono, R/R Hodgkin: ORR 44% (63% at 600 mg) |
Pending |
| CONQUER |
Tue |
Dual-epitope anti-CD5 CAR-T, R/R T-ALL/PTCL: ORR 77.8% (100% at RP2D) |
Pending |
| Revumenib (post-HSCT) |
Tue |
Revumenib maintenance post-transplant, KMT2Ar/NPM1m/NUP98r leukemia (Abs 6505) |
Pending |
| Olverembatinib 2L |
Sat |
2L olverembatinib, CML-CP: 91.3% CCyR, 60.9% MMR by cycle 24 |
Pending |
Melanoma / rare
| Trial |
Day |
Result |
PC? |
| OptimUM-02 |
Mon |
Darovasertib + crizotinib vs ICT, 1L HLA-A*02:01-neg metastatic uveal melanoma: mPFS 6.9 vs 3.1 mo (HR 0.42); ORR 37.1% vs 5.8% |
Pending |
| SARC041 |
Sun |
(see Plenary — abemaciclib in dedifferentiated liposarcoma) |
Yes |
Per-trial template
Each trial file follows this schema:
# <Trial acronym / name> — <Drug regimen, indication, line>
> **Abstract:** <abstract #> · **Session:** <session, date, time CT> · **Embargo:** <date>
## At a glance
- **Sponsor:** · **PI / presenter:** · **NCT ID:** · **Phase:** · **Design:**
- **N:** · **Primary endpoint(s):** · **Comparator:** · **Indication:** · **Line:**
## Headline result
## Mechanism / class
## Discussant takeaway
## Practice-changing?
## Cross-links
## Sources